Drug Search Results
More Filters [+]

PE-0105

Alternative Names: PE-0105, PE 0105, PE0105
Latest Update: 2023-12-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PD-1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: HyaMab Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PE-0105

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Cervical Cancer|Head and Neck Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

YL-0116-002

P2

Not yet recruiting

Cervical Cancer|Ovarian Cancer|Head and Neck Cancer

2027-08-31

23%

YL-0116-002

P2

Not yet recruiting

Cervical Cancer|Ovarian Cancer|Head and Neck Cancer

2027-08-31

23%

PE0116-Ib/II

P2

Recruiting

Oncology Solid Tumor Unspecified

2026-09-01

57%

PE0116-Ib/II

P2

Recruiting

Oncology Solid Tumor Unspecified

2026-09-01

57%

Recent News Events

Date

Type

Title